SCHEMBL4412498

SCHEMBL4412498

O=C1N(c2c(Cl)cc(F)c(O)c2F)Cc2cnc(NC3CCC(O)CC3)nc2N1C1CCCC1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 14/20 0.47
FGFR4 P22455 11/20 0.47
FGFR2 P21802 8/20 0.47
FGFR3 P22607 8/20 0.47
MAPK14 Q16539 3/20 0.44
EGFR P00533 1/20 0.39
FYN P06241 1/20 0.39
PDGFRB P09619 1/20 0.39
PDGFRA P16234 1/20 0.39
PRKACA P17612 1/20 0.39
PRKACG P22612 1/20 0.39
PRKACB P22694 1/20 0.39
MAPK1 P28482 1/20 0.39
KDR P35968 1/20 0.39
EPHB3 P54753 1/20 0.39
MAPK8 P45983 2/20 0.38
MAPK9 P45984 2/20 0.38
MAPK10 P53779 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4398860 0.97 FGFR1 (0.45) FGFR1FGFR4FGFR2FGFR3MAPK14
SCHEMBL4412725 0.94 FGFR1 (0.47) FGFR1FGFR4FGFR2FGFR3MAPK14
SCHEMBL4551391 0.91 FGFR1 (0.49) FGFR1FGFR4FGFR2FGFR3
SCHEMBL4404489 0.90 FGFR1 (0.45) FGFR1FGFR4FGFR2FGFR3MAPK14
SCHEMBL4551556 0.88 FGFR1 (0.47) FGFR1FGFR4FGFR2FGFR3EGFR
SCHEMBL4411835 0.85 MAPK14 (0.44) FGFR1FGFR4FGFR2FGFR3MAPK14
SCHEMBL4401600 0.84 MAPK14 (0.43) FGFR1FGFR4FGFR2FGFR3MAPK14
SCHEMBL4406062 0.84 FGFR4 (0.43) FGFR1FGFR4FGFR2FGFR3MAPK14
SCHEMBL4405368 0.83 FGFR4 (0.52) FGFR1FGFR4FGFR2FGFR3MAPK14
SCHEMBL4404480 0.82 FGFR1 (0.48) FGFR1FGFR4FGFR2FGFR3MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1549651-B1 PYRIMIDOPYRIMIDONES AS KINASE INHIBITORS WARNER LAMBERT CO (US) 2009-12-23 EP disclosed
US-7196090-B2 Kinase inhibitors WARNER-LAMBERT COMPANY (US) 2007-03-27 US disclosed
US-20040019210-A1 Kinase inhibitors CHIVIKAS CONNOLLY CLEO J (US) 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019210-A1 Kinase inhibitors CDK2, CDK1, CDK4 FGFR1 88/4885FGFR4 191/4885FGFR2 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.